Print Page   |   Contact Us   |   Sign In   |   Join Now
News & Press: Industry News

New NIDDK-focused Assay Development and Screening R01 Program Announced

Tuesday, August 2, 2016   (0 Comments)
Posted by: Megan Grant
Share |
The NIH/NIDDK has just released a new program to support assay development and screening. This is specific to projects related to endpoints that fall within the primary mission of the NIDDK. Projects in areas that are primarily within the missions of other Institutes or Centers (ICs) of the NIH are not appropriate for this FOA and will not be supported. For example, research on diabetic retinopathy should be submitted to the NEI, research on cardiovascular disease, hypertension or dyslipidemia should be submitted to the NHLBI, and research on cancers should be submitted to the NCI. 

“Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01)”

http://grants.nih.gov/grants/guide/pa-files/PA-16-374.html

 

Aaron C. Pawlyk, Ph.D.

Program Director for Pharmacogenomics and Drug Discovery

National Institute of Diabetes and Digestive and Kidney Diseases

Building 2DEM, Room 7207

6707 Democracy Boulevard, Bethesda, MD 20892

Tel: 301-451-7299, Fax: 301-480-0475

Email: pawlykac@mail.nih.gov


Association Management Software  ::  Legal